University of California San Francisco

Brian M. Till, MD

Brian Till
Brian M. Till, MD

Clinical Fellow (PGY-8)
Thoracic Surgery

[email protected]

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.
    Baek G, Varma G, Yamshon S, van Besien H, Bartlett NL, Watkins M, Shah HR, Baron K, Merryman RW, Falade AS, Svoboda J, Prischak S, D'Angelo C, Lukowski JD, Advani RH, Yeung AH, Rosenberg M, Voutsinas J, Di M, Lynch R, Poh C, Raghunathan V, Shadman M, Smith S, Till BG, Ujjani C, Diefenbach CS, Gopal AK| | PubMed
  2. Combined Heart-Liver Transplant in a Patient With End-Stage Liver Disease and Contained Rupture of an Aortic Root Pseudoaneurysm.
    Miller PN, Till B, Fiedler AG| | PubMed
  3. CD20-Targeted α-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma.
    O'Steen S, Lee SY, Comstock ML, Kehret AR, Lin Y, Hamlin DK, Dexter SL, Hippe DS, Gooley TA, Wilbur DS, Li Y, Walter RB, Till B, Orozco JJ, Green DJ| | PubMed
  4. Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.
    Ozog S, Krantz EM, Tindbaek K, Munoz J, Liu WL, Chalal C, Pernikoff S, Yahya K, Stevens-Ayers T, Dasgupta S, Cowan AJ, Green DJ, Gauthier J, Till BG, Gardner RA, Shadman M, Bleakley M, Boeckh M, Boonyaratanakornkit J, Turtle CJ, Hill JA| | PubMed
  5. Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.
    Liang EC, Jeon Y, Qiao Y, Wu X, Huang JJ, Portuguese AJ, Basom R, Torkelson A, Kirchmeier D, Braathen K, Cowan AJ, Shadman M, Hirayama AV, Till BG, Kimble EL, Wu Q, Gauthier J| | PubMed
  6. Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.
    Ho C, Kennedy N, Di M, Gopal AK, Lynch RC, Ng K, Wu QV, Poh C, Raghunathan V, Rasmussen H, Shadman M, Till BG, Ujjani CS, Smith SD| | PubMed
  7. Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.
    Poh C, Chen X, Voutsinas J, Naresh K, Dizon JJ, Shadman M, Lynch RC, Till BG, Ujjani CS, Di M, Raghunathan V, Warren EH, Smith SD, Wu QV, Cherian S, Gopal AK| | PubMed
  8. Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials.
    Portuguese AJ, Tuazon SA, Pont MJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu VQ, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Libby EN, Chapuis AG, Milano F, Riddell SR, Green DJ, Cowan AJ| | PubMed
  9. Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.
    Poh C, Voutsinas JM, Shadman M, Lynch RC, Warren EH, Crimp CA, Till BG, Ujjani CS, Di M, Raghunathan V, Smith SD, Wu QV, Shinohara MM, Gopal AK| | PubMed
  10. Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
    Lynch RC, Cassaday RD, Smith SD, Cowan AJ, Warren EH, Shadman MS, Till BG, Ujjani CS, Morris K, Rasmussen H, Voutsinas J, Gopal AK| | PubMed